BNGO Jan 2025 1.000 put
| Previous close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.3500 |
| Ask | 0.4500 |
| Strike | 1.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.4500 - 0.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 271 |
GlobeNewswireBionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples. OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM. Som
- GlobeNewswire
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome karyotype analysisDiagens will become an original equipment manufacturing (OEM
- GlobeNewswire
Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically relevant genomic variations in pediatric B-cell acute lymphoblastic leukemia (B-ALL). The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM
